scholarly journals Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: A novel drug carrier for cancer targeting therapy

1999 ◽  
Vol 81 (7) ◽  
pp. 1155-1161 ◽  
Author(s):  
S Tsunoda ◽  
I Ohizumi ◽  
J Matsui ◽  
K Koizumi ◽  
Y Wakai ◽  
...  
2021 ◽  
Vol 4 (3) ◽  
pp. 2723-2731
Author(s):  
Lijun Xie ◽  
Renfu Li ◽  
Biyun Zheng ◽  
Zuoxu Xie ◽  
Xuefen Fang ◽  
...  

2012 ◽  
Vol 29 (2) ◽  
pp. 266-267 ◽  
Author(s):  
Yunxin Chen ◽  
Hui Yao ◽  
Erika J. Thompson ◽  
Nizar M. Tannir ◽  
John N. Weinstein ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Lindsey Abel ◽  
Arda Durmaz ◽  
Rong Hu ◽  
Colin Longhurst ◽  
Andrew M. Baschnagel ◽  
...  

Abstract Background Patient-derived xenografts established from human cancers are important tools for investigating novel anti-cancer therapies. Establishing PDXs requires a significant investment and many PDXs may be used infrequently due to their similarity to existing models, their growth rate, or the lack of relevant mutations. We performed this study to determine whether we could efficiently establish PDXs after cryopreservation to allow molecular profiling to be completed prior to implanting the human cancer. Methods Fresh tumor was split with half used to establish a PDX immediately and half cryopreserved for later implantation. Resulting tumors were assessed histologically and tumors established from fresh or cryopreserved tissues compared as to the growth rate, extent of tumor necrosis, mitotic activity, keratinization, and grade. All PDXs were subjected to short tandem repeat testing to confirm identity and assess similarity between methods. Results Tumor growth was seen in 70% of implanted cases. No growth in either condition was seen in 30% of tumors. One developed a SCC from the immediate implant but a lymphoproliferative mass without SCC from the cryopreserved specimen. No difference in growth rate was seen. No difference between histologic parameters was seen between the two approaches. Conclusions Fresh human cancer tissue can be immediately cryopreserved and later thawed and implanted to establish PDXs. This resource saving approach allows for tumor profiling prior to implantation into animals thus maximizing the probability that the tumor will be utilized for future research.


2019 ◽  
Vol 4 (40) ◽  
pp. eaaw9159 ◽  
Author(s):  
Yu Si ◽  
Simon F. Merz ◽  
Philipp Jansen ◽  
Baoxiao Wang ◽  
Kirsten Bruderek ◽  
...  

A high intratumoral frequency of neutrophils is associated with poor clinical outcome in most cancer entities. It is hypothesized that immunosuppressive MDSC (myeloid-derived suppressor cell) activity of neutrophils against tumor-reactive T cells contributes to this effect. However, direct evidence for such activity in situ is lacking. Here, we used whole-mount labeling and clearing, three-dimensional (3D) light sheet microscopy and digital image reconstruction supplemented by 2D multiparameter immunofluorescence, for in situ analyses of potential MDSC–T cell interactions in primary human head and neck cancer tissue. We could identify intratumoral hotspots of high polymorphonuclear (PMN)–MDSC and T cell colocalization. In these areas, the expression of effector molecules Granzyme B and Ki67 in T cells was strongly reduced, in particular for T cells that were in close proximity or physically engaged with PMN-MDSC, which expressed LOX-1 and arginase I. Patients with cancer with evidence for strong down-regulation of T cell function by PMN-MDSC had significantly impaired survival. In summary, our approach identifies areas of clinically relevant functional interaction between MDSC and T cells in human cancer tissue and may help to inform patient selection in future combination immunotherapies.


2013 ◽  
Vol 4 ◽  
Author(s):  
Tuuli Kaambre ◽  
Vladimir Chekulayev ◽  
Igor Shevchuk ◽  
Kersti Tepp ◽  
Natalja Timohhina ◽  
...  

2015 ◽  
Vol 7 (1) ◽  
pp. 71-80 ◽  
Author(s):  
Nima Abbassi-Ghadi ◽  
Emrys A. Jones ◽  
Kirill A. Veselkov ◽  
Juzheng Huang ◽  
Sacheen Kumar ◽  
...  

The repeatability and reproducibility of DESI-MS for the measurement of lipid ion intensities in human cancer tissue is 22 ± 7% and 18 ± 8%, respectively.


Author(s):  
Lindsey Abel ◽  
Arda Durmaz ◽  
Rong Hu ◽  
Colin Longhurst ◽  
Jacob G. Scott ◽  
...  

AbstractBackgroundPatient-derived xenografts established from human cancers are important tools for investigating novel anti-cancer therapies. Establishing PDXs requires a significant investment and many PDXs may be used infrequently due to their similarity to existing models, their growth rate, or the lack of relevant mutations. We performed this study to determine whether we could efficiently establish PDXs after cryopreservation to allow molecular profiling to be completed prior to implanting the human cancer.MethodsFresh tumor was split with half used to establish a PDX immediately and half cryopreserved for later implantation. Resulting tumors were assessed histologically and tumors established from fresh or cryopreserved tissues compared as to the growth rate, extent of tumor necrosis, mitotic activity, keratinization, and grade. All PDXs were subjected to short tandem repeat testing to confirm identity and assess similarity between methods.ResultsTumor growth was seen in 70% of implanted cases. No growth in either condition was seen in 30% of tumors. One developed a SCC from the immediate implant but a lymphoproliferative mass without SCC from the frozen specimen. No difference in growth rate was seen. No difference between histologic parameters was seen between the two approaches.ConclusionFresh human cancer tissue can be immediately cryopreserved and later thawed and implanted to establish PDXs. This resource saving approach allows for tumor profiling prior to implantation into animals thus maximizing the probability that the tumor will be utilized for future research.


1953 ◽  
Vol 29 (2) ◽  
pp. 59-60 ◽  
Author(s):  
Munio KOTAKE ◽  
Akio OHSUKA

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P35-P35 ◽  
Author(s):  
Nopawan Vorasubin ◽  
Quyen To Nguyen ◽  
Emilia Olson ◽  
Todd A Aguilera ◽  
Tao Jiang ◽  
...  

Objective 1) Assess activatable cell penetrating peptide (ACPP) uptake by human tissue. 2) Compare ACPP uptake in normal and cancer tissue. Methods ACPPs are peptides that become activated for cellular uptake by cleavage in the presence of specific proteases. Fluorescently tagging ACPPs and designing a cleavage site recognized by proteases abundant in cancer allows for selective uptake and imaging. Cleavable ACPPs consist of L-amino acids linkers, while uncleavable linkers consist of corresponding D-isomers. To assess ACPP uptake by human tissue, we imaged freshly ressected surgical specimens following incubation with ACPP. Uptake was analyzed by measuring average fluorescent intensities (AFI) for histologically identified areas of cancer and normal tissue. Standardized uptake value (SUV) measurements, which represents fluorescence uptake per given tissue weight, and zymography were also performed. Results Average cancer-to-normal AFI ratio when treated with cleavable ACPP was 2.6±0.6 (p=0.003) and with uncleavable control was 1.4±0.5 (p=0.5). Considering cancer tissue alone, average AFI was 22.5 ±2.2 when treated with cleavable and 11.4 ±1.2 when treated with uncleavable ACPP (p=0.004). Tissue SUV when treated with cleavable ACPP was 2.5±0.8mg-1, whereas tissue treated with control ACPP was 1.7±1.0mg-1 (p=0.24). Zymography results show that inactive protease is ubiquitous in cancer and normal tissue while active form is more abundant in cancer. Conclusions In freshly resected human cancer tissue, uptake of cleavable ACPP is ∼2-fold greater than that of uncleavable ACPP. Furthermore, cleavable ACPP uptake is ∼2.5-fold greater in cancer compared to normal tissue. This differential uptake can potentially be used for in vivo imaging of cancer to guide surgical resection.


Sign in / Sign up

Export Citation Format

Share Document